Chandra Vidhan, Allen Mark S, Nichols Francis C, Deschamps Claude, Cassivi Stephen D, Pairolero Peter C
Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Mayo Clin Proc. 2006 May;81(5):619-24. doi: 10.4065/81.5.619.
To analyze the outcome of surgical resection for patients with small cell lung cancer (SCLC).
We identified all patients who underwent thoracotomy for SCLC at our institution from January 1985 to July 2002. All patients were staged using the American Joint Committee on Cancer TNM system.
The median age of the 77 patients (44 men and 33 women) was 65 years (range, 35-85 years). Operations performed included thoracotomy with biopsy of hilar mass in 10 patients, wedge excision in 30 (6 with talc pleurodesis), segmentectomy in 4, lobectomy in 28, bilobectomy in 3, and pneumonectomy in 2. Mediastinal lymphadenectomy was performed in 50 patients and lymph node sampling in 19. Postoperative therapy Included chemotherapy alone in 20 patients, radiation therapy in 3, and combined chemotherapy and radiation therapy in 40. Median tumor diameter was 4 cm (range, 1.0-10.0 cm). Postsurgical tumor stage was IA in 7 patients, IB in 11, IIA in 8, IIB in 7, IIIA in 30, IIIB in 10, and IV in 4. A total of 19 patients (25%) had complications: atrial arrhythmia in 7 patients, pneumonia in 6, prolonged air leak in 3, and myocardial infarction, postoperative bleeding, and cerebrovascular accident in 1 each. Operative mortality was 3% (2/77). Follow-up ranged from 4 days to 170 months (median, 19 months). At last follow-up, 20 patients were alive. The estimated overall 5-year survival was 27% when excluding the 10 patients who underwent a biopsy without additional surgery. Five-year survival for stage I and II combined (n=33) was 38% compared with only 16% for stage III and IV combined (n=34) (P=.02). Overall median survival was 24 months; median survival for patients who underwent curative surgery was 25 months compared with 16 months for those who had a palliative procedure (P=.34).
Pulmonary resection in patients with stage I or stage II SCLC is safe with low mortality and morbidity. Curative resection is associated with long-term survival in early stage SCLC in some patients and should be considered in selected patients.
分析小细胞肺癌(SCLC)患者手术切除的结果。
我们确定了1985年1月至2002年7月间在我院因SCLC接受开胸手术的所有患者。所有患者均采用美国癌症联合委员会TNM系统进行分期。
77例患者(44例男性和33例女性)的中位年龄为65岁(范围35 - 85岁)。所进行的手术包括10例对肺门肿块进行活检的开胸手术、30例楔形切除术(其中6例同时行滑石粉胸膜固定术)、4例肺段切除术、28例肺叶切除术、3例双肺叶切除术和2例全肺切除术。50例患者进行了纵隔淋巴结清扫术,19例进行了淋巴结采样。术后治疗包括20例单纯化疗、3例放疗以及40例化疗联合放疗。肿瘤中位直径为4 cm(范围1.0 - 10.0 cm)。术后肿瘤分期为IA期7例、IB期11例、IIA期8例、IIB期7例、IIIA期30例、IIIB期10例和IV期4例。共有19例患者(25%)出现并发症:7例房性心律失常、6例肺炎、3例持续性漏气,各有1例发生心肌梗死、术后出血和脑血管意外。手术死亡率为3%(2/77)。随访时间从4天至170个月(中位时间19个月)。在最后一次随访时,20例患者存活。排除10例仅接受活检而未进行额外手术的患者后,估计总体5年生存率为27%。I期和II期联合(n = 33)的5年生存率为38%,而III期和IV期联合(n = 34)仅为16%(P = 0.02)。总体中位生存期为24个月;接受根治性手术患者的中位生存期为25个月,而接受姑息性手术患者为16个月(P = 0.34)。
I期或II期SCLC患者的肺切除术安全,死亡率和发病率低。根治性切除在部分早期SCLC患者中与长期生存相关,应在合适的患者中考虑。